PH24309A - Cycloalkylamides of(8beta)-1-alkyl-6-(substituted)-ergolines and pharmaceutical formulations thereof - Google Patents

Cycloalkylamides of(8beta)-1-alkyl-6-(substituted)-ergolines and pharmaceutical formulations thereof

Info

Publication number
PH24309A
PH24309A PH37059A PH37059A PH24309A PH 24309 A PH24309 A PH 24309A PH 37059 A PH37059 A PH 37059A PH 37059 A PH37059 A PH 37059A PH 24309 A PH24309 A PH 24309A
Authority
PH
Philippines
Prior art keywords
alkyl
substituted
cycloalkylamides
8beta
ergolines
Prior art date
Application number
PH37059A
Other languages
English (en)
Inventor
Mark Mortensen Foreman
William Lee Garbrecht
Kathleen Rose Whitten
Gifford Purnell Marzoni
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH24309A publication Critical patent/PH24309A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PH37059A 1987-06-15 1988-06-13 Cycloalkylamides of(8beta)-1-alkyl-6-(substituted)-ergolines and pharmaceutical formulations thereof PH24309A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6228587A 1987-06-15 1987-06-15

Publications (1)

Publication Number Publication Date
PH24309A true PH24309A (en) 1990-05-29

Family

ID=22041482

Family Applications (1)

Application Number Title Priority Date Filing Date
PH37059A PH24309A (en) 1987-06-15 1988-06-13 Cycloalkylamides of(8beta)-1-alkyl-6-(substituted)-ergolines and pharmaceutical formulations thereof

Country Status (22)

Country Link
EP (1) EP0296748B1 (ko)
JP (1) JP2653835B2 (ko)
KR (1) KR960010454B1 (ko)
CN (1) CN1019451B (ko)
AT (1) ATE87921T1 (ko)
AU (1) AU613641B2 (ko)
CA (1) CA1339661C (ko)
DE (1) DE3880022T2 (ko)
DK (1) DK322588A (ko)
EG (1) EG18586A (ko)
ES (1) ES2054806T3 (ko)
HK (1) HK77693A (ko)
HU (2) HU203344B (ko)
IE (1) IE61884B1 (ko)
IL (1) IL86725A (ko)
MX (1) MX11866A (ko)
NZ (1) NZ225022A (ko)
PH (1) PH24309A (ko)
PT (1) PT87716B (ko)
SU (1) SU1597103A3 (ko)
UA (1) UA6022A1 (ko)
ZA (1) ZA884222B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902691A (en) * 1988-12-19 1990-02-20 Eli Lilly And Company Heteroalkylamides of (8-β)-1-alkyl-6-(substituted)ergolines useful for blocking 5HT2 receptors
IT1232692B (it) * 1989-08-04 1992-03-04 Poli Ind Chimica Spa Derivati ergolinici con attivita' dopaminergica
US5141944A (en) * 1990-04-11 1992-08-25 Eli Lilly And Company N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
US5043341A (en) * 1990-04-11 1991-08-27 Eli Lilly And Company N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
CA2218143A1 (en) * 1995-04-18 1996-10-24 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor
EP2053438B1 (en) 1998-05-26 2014-04-16 Canon Kabushiki Kaisha Focus detecting device, distance measuring device, and optical apparatus for adjusting focus
EP2515654A4 (en) 2009-12-23 2013-04-24 Map Pharmaceuticals Inc NEW ERGOLINANALOGA
CN102775402B (zh) * 2011-05-13 2015-08-26 上海现代制药股份有限公司 一种制备二氢麦角酸的中间体及其制备方法
MX2013015373A (es) 2011-06-23 2014-02-11 Map Pharmaceuticals Inc Nuevos analogos de fluoroergolina.
SG11201403434YA (en) 2011-12-19 2014-09-26 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
SG10201506202RA (en) 2011-12-21 2015-09-29 Map Pharmaceuticals Inc Novel neuromodulatory compounds
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH386441A (de) * 1961-02-17 1965-01-15 Sandoz Ag Verfahren zur Herstellung von am Indolstickstoff substituierten Derivaten der Lysergsäure-Reihe
GB982737A (en) * 1961-05-08 1965-02-10 Westminster Bank Ltd Improvements in or relating to lysergic acid compounds
GB996062A (en) * 1961-07-13 1965-06-23 Westminster Bank Ltd Improvements in or relating to lysergic acid compounds

Also Published As

Publication number Publication date
KR960010454B1 (ko) 1996-08-01
SU1597103A3 (ru) 1990-09-30
UA6022A1 (uk) 1994-12-29
DK322588D0 (da) 1988-06-14
IE61884B1 (en) 1994-11-30
MX11866A (es) 1993-12-01
ATE87921T1 (de) 1993-04-15
NZ225022A (en) 1990-07-26
DK322588A (da) 1989-02-01
HU203344B (en) 1991-07-29
KR890000482A (ko) 1989-03-14
PT87716B (pt) 1992-10-30
HU211235A9 (en) 1995-11-28
AU613641B2 (en) 1991-08-08
IE881788L (en) 1988-12-15
DE3880022T2 (de) 1993-08-19
CA1339661C (en) 1998-02-10
HUT47271A (en) 1989-02-28
JP2653835B2 (ja) 1997-09-17
HK77693A (en) 1993-08-13
JPS6416781A (en) 1989-01-20
DE3880022D1 (de) 1993-05-13
ES2054806T3 (es) 1994-08-16
CN1030586A (zh) 1989-01-25
AU1765288A (en) 1988-12-15
EP0296748B1 (en) 1993-04-07
EG18586A (en) 1993-08-30
ZA884222B (en) 1990-02-28
IL86725A (en) 1993-01-14
PT87716A (pt) 1988-07-01
CN1019451B (zh) 1992-12-16
IL86725A0 (en) 1988-11-30
EP0296748A1 (en) 1988-12-28

Similar Documents

Publication Publication Date Title
EP0299209A3 (en) Pyrazolopyridine compound and processes for preparation thereof
PH24309A (en) Cycloalkylamides of(8beta)-1-alkyl-6-(substituted)-ergolines and pharmaceutical formulations thereof
NZ214156A (en) Quindone derivatives and pharmaceutical compositions
GR3005990T3 (ko)
IL134894A (en) 2-substituted-1,3,4,5-tetrahydro-2h-gamma-carbolines, their preparation and pharmaceutical compositions containing them
EP0192210A3 (en) New cephem compounds and processes for preparation thereof
IL86080A0 (en) Bicyclic compounds,processes for preparation thereof and pharmaceutical composition comprising the same
EP0285284A3 (en) N-phenethylaminoalkyl-benzamide anti-arrhythmia agents
TW221429B (ko)
EP0328282A3 (en) Pharmaceutical
GR3007219T3 (ko)
NO872874L (no) Amid-derivater.
GR3007498T3 (ko)
GR3006108T3 (ko)
GR3017435T3 (en) Antihypertensive 3-piperidinyl-indazole derivatives.
TW275629B (ko)
EP0250814A3 (en) Prophylactic and curing composition containing a 8-chlorobenzothiazepine compound and its use
GR3006223T3 (ko)
EP0272849A3 (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases